Corcept Therapeutics Incorporated (CORT)

First Trust Advisors LP trimmed its position in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 41.9% during the undefined quarter, according to the company in its most recent filing with the Secu...

Cerity Partners LLC grew its stake in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) by 21.4% during the second quarter, according to the company in its most recent disclosure with the SEC...

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?...

CORT leans on rising Korlym sales while awaiting key relacorilant FDA decisions that could broaden its growth path in 2026....

Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) have earned an average rating of "Hold" from the seven ratings firms that are presently covering the firm, Marketbeat repor...

Envestnet Asset Management Inc. raised its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 22.3% during the second quarter, according to the company in its most recent Form 13F filing wit...

Aviva PLC trimmed its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) by 36.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Sec...

CORT's third-quarter earnings and sales miss estimate. The company cuts guidance despite a 14% year-over-year rise in revenues....

Corcept Therapeutics Incorporated ( CORT ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Sean M...

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.41 per share a year ago....